Allarity Therapeutics
ALLARITY THERAPEUTICS INC Logo
About ALLARITY THERAPEUTICS INC
Allarity Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics for patients with difficult-to-treat cancers. The company’s lead program, stenoparib, is an orally available small molecule inhibitor targeting advanced recurrent ovarian cancer. Allarity leverages its proprietary Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes, advancing precision medicine in oncology. The company operates in the United States and Denmark.
Year founded
2021
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
